Role of metallothionein in cisplatin sensitivity of germ-cell tumours

International Journal of Cancer

Volumn 85, Issue 6, 2000, Pages 777-781

  Meijer, Coby ^a   Timmer, Albertus ^a   De Vries, Elisabeth G E ^a   Groten, John P ^b   Knol, Ageeth ^a   Zwart, Nynke ^a   Dam, Wendy A ^a   Sleijfer, Dirk Th ^a   Mulder, Nanno H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLUTATHIONE PEROXIDASE; METALLOTHIONEIN; PROTEIN P53;

ARTICLE; CELLULAR DISTRIBUTION; COLON CARCINOMA; DISEASE ASSOCIATION; DRUG SENSITIVITY; GERM CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CISPLATIN; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; GERMINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METALLOTHIONEIN; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034107685     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000315)85:6<777::AID-IJC6>3.0.CO;2-D     Document Type: Article

References (21)

1. ANDREWS, P.A. and HOWELL, S.B., Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43 (1990).
2. BAHNSON, R.R., BASU, A. and LAZO, J.S., The role of metallothioneins in anti-cancer-drug resistance. In: R.F. Ozols (ed.), Molecular and clinical advances in anti-cancer-drug resistance, pp. 251-260, Kluwer, Boston (1991).
3. BEDFORD, P., FICHTINGER-SCHEPMAN, A.M.J., SHELLARD, S.A., WALKER, C., MASTERS, J.R.W. and HILL, B.T., Differential repair of platinum-DNA adducts in human bladder-and testicular-tumour continuous cell lines. Cancer Res., 48, 3019-3024 (1988).
4. CHIN, J.L., BANERJEE, D., KADHIM, S.A., KONTOZGLOU, T.E., CHAUVIN, P.J. and CHERIAN, M.G., Metallothionein in testicular germ-cell tumours and drug resistance. Cancer, 72, 3029-3035 (1993).
5. DOUGLAS-JONES, A.G., NAVABI, H., MORGAN, J.M. and JASANI, B., Immunoreactive p53 and metallothionein expression in duct carcinoma in situ of the breast. Virchows Arch., 430, 373-379 (1997).
6. EID, H., GECZI, L., BODROGI, I. and BAK, M., Do metallothioneins affect the response to treatment in testis cancers? J. Cancer Res. clin. Oncol., 124, 31-36 (1998).
7. EID, H., VAN DER LOOIJ, M., INSTITORIS, E., GÉCZI, L., BODROGI, E.O. and MIHÁLY, B., Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res., 17, 2663-2670 (1997).
8. FISHER, E.H. and DAVIE, E.W., Recent excitement regarding metallothionein. Proc. nat. Acad. Sci. (Wash.), 95, 3333-3334 (1998).
9. GROTEN, J.P., KOEMAN, J.H., NESSELROOIJ, J.H.J., LUTEN, J.B., FENTENER VAN VLISSINGEN, J.M., STEENHIUS, W.S. and VAN BLADEREN, P.J., Comparison of renal toxicity after long-term oral administration of cadmium chloride and cadmium-metallothionein in rats. Fundam. appl. Toxicol., 23, 544-552 (1994).
10. GUIFFRÈ, G., BARRESI, G., STURNIOLO, G.C., SARNELLI, R., D'INCA, R. and TUCCARE, G., Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenomas and in adenocarcinomas and their metastases. Histopathology, 29, 347-354 (1996).
11. HAERSLEV, T., JACOBSEN, G.K. and ZEDELER, K., The prognostic significance of immunohistochemical detectable metallothionein in primary breast carcinomas. Acta path. microbiol. immunol. scand., 103, 279-285 (1995).
12. JASANI, B. and SCHMID, K.W., Significance of metallothionein over-expression in human tumours. Histopathology, 31, 211-214 (1997).
13. KÄGI, J.H.R. and SCHAFFER, A., Biochemistry of metallothionein. Biochemistry, 27, 8509-8515 (1988).
14. KONDO, Y., KUO, S.-M., WATKINS, S.C. and LAZO, J.S., Metallothionein localization and cisplatin resistance in human hormone-independent prostatic-tumour cell lines. Cancer Res., 55, 474-477 (1995).
15. KONTOZOGLOU, T.E., BANERJEE, D. and CHERIAN, M.G., Immunohistochemical localization of metallothionein in human testicular-embryonalcarcinoma cell lines. Virchows Arch. A., Pathol. Anal. Histopathol., 415, 545-549 (1989).
16. KOROPATNICK, J. and PEARSON, J., Altered cisplatin and cadmium resistance and cell survival in Chinese ovary cells expressing mouse metallothionein. Mol. Pharmacol., 44, 44-50 (1993).
17. LOEHRER, P.J. and EINHORN, L.H., Cisplatin. Ann. intern. Med., 100, 704-713 (1984).
18. MASTERS, J.R.W., THOMAS, R., HALL, A.G., HOGARTH, L., MATHESON, E.C., CATTAN, A.R. and LOHRER, H., Sensitivity of testis-tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Europ. J. Cancer, 32A, 1248-1253 (1996).
19. SARK, M.W.J., TIMMER-BOSSCHA, H., MEIJER, C., UGES, D.R.A., SLUITER, W.J., PETERS, W.H.M., MULDER, N.H. and DE VRIES, E.G.E., Cellular basis for differential sensitivity to cisplatin in human germ-cell-tumour and colon-carcinoma cell lines. Brit. J. Cancer, 71, 684-690 (1995).
20. SCHENKMAN, N.S., SESTERHENN, I.A., WASHINGTON, L., TONG, Y.A., WEGHORST, C.M., BUZARD, G.S., SRIVASTAVA, S. and MOUL, J.W., Increased p53 protein does not correlate to p53-gene mutations in microdissected human testicular germ-cell tumours. J. Urol., 154, 617-621 (1995).
21. WOO, E.S. and LAZO, J.S., Nucleocytoplasmic functionality of metallothionein. Cancer Res., 57, 4236-4241 (1997).